Concurrent (CCUR) the most overlooked stock on the NASDAQ today is breaking out up 9 out of past 10 days and 14 out of past 17 days! Ready to explode to double digits in the days ahead! CCUR is currently only $7.92 has huge cash position of $24.6mm and no debt, enterprise value of only $48.2mm or just 0.77x revenue when its closest comparison Seachange (SEAC) and hit a new 52-week high last week and is trading with enterprise value/revenue ratio of 1.85, which will value CCUR at $15+ per share - double its current share price!
CCUR's VOD technology has been deployed 212 times across 4 continents with 2.4mm+ concurrent streams and reach of 50mm homes worldwide! CCUR's business is about to boom big time from cable TV service providers investing heavily for the new multi-screen IP connected video world! Virgin Media (VMED) announced last week that their new Virgin TV Anywhere service that allows their 3.8mm subscribers to watch on demand content from any location using tablets or smartphones, is now being powered by CCUR's MediaHawk CDN platform! CCUR's EPS last quarter was double quarter before and quadruple two quarters ago, but this is nothing compared to CCUR's EPS growth in upcoming quarters from their new VMED multi-screen video delivery deal!
CCUR will receive HUGE exposure next week when they launch their new eFactor technology at an expo in Vegas, which allows service providers to dynamically apply changes to content during the streaming process. With eFactor, video service providers can easily and cost-effectively adapt content on-the-fly, to provide subscribers with the best possible viewing experience. CCUR's eFactor supports linear broadcast, video on demand, live events, and time-shifted video services to any device, over any network. CCUR's new breakthrough eFactor advanced policy controls will allow their clients to create personalized video streams for each subscriber and generate greater revenue from the streams they are already serving!
Pharmaceuticals Inc. (OPTR), the antibiotics maker that’s weighing a sale, drew interest from drugmakers including GlaxoSmithKline Plc (GSK) and Japan’s Astellas Pharma Inc. (4503), said two people familiar with the matter. The shares surged.
The maker of the antibiotic Dificid aims to fetch as much as $1 billion in a possible auction, said the people, who asked not to be named because the process is private. Optimer also attracted interest from Cubist Pharmaceuticals Inc. (CBST) and AstraZeneca Plc, said one of the people.
Buying Optimer would allow the drugmakers to generate more revenue from hospitals, as Dificid, the company’s sole drug on the market, treats a bacterium linked to intestinal infections in hospitalized patients. The drugmaker also may prove attractive to peers that already distribute to medical facilities, because they could use existing distribution channels to reduce costs.
Optimer shares climbed as much as 24 percent following Bloomberg’s report. They advanced to $14.48 at 9:37 a.m. in New York, giving the company a market value of almost $700 million.
Optimer said on Feb. 27 that the board would examine “a full range” of strategic alternatives. The company is working with Centerview Partners LLC and JPMorgan Chase & #$%$ the process.
Former Chairman Michael Chang left Optimer last year after the board found that he failed to identify and manage conflict of interest issues tied to a stock grant. The company also replaced Chief Executive Officer Pedro Lichtinger in February, when Optimer disclosed the board’s strategic review.
Representatives for JPMorgan, Astellas, Glaxo, Cubist and AstraZeneca declined to comment. Optimer spokesman David Walsey didn’t return calls seeking comment.
Hi Ucited. I didn't see any new press release from OPTR, so I expect it was an analyst making his projections and listing those previously suspected to be candidates. I welcome their suggestions, but I would welcome more a bid and competition for buying OPTR.
Hey Pro, I suppose you missed putting the 1 before the 4, but you are still low. Did you get your short cover at $7 like you promised you would? Oops, it never got there. Oh my.
It's worth no more than 4 pps (at best)....you should sell now cause this thing will come crashing down once the deal falls through and investors realize that generic Vanco holds 90% of the market!
Love OPTR long... take a look at RCON it's setting up for Thursday to breakout if you look at the technicals. If they are wrong and they won't be well RCON is stringing together nice earnings and this next pending report should launch RCON share price.
Take a look and use some good old fashion DD.
I know that, several months ago, I had previously stated that this would be sold at $15 and that today's press release stated that it could fetch as much as a billion, which would put the share price at just over $20. However, I'm hearing that it will go for $17-$18.
I'll take it!
All of the above, just one man's opinion.
I'm going to be watching OPTR closely. This is an interesting one, but is already showing great signs of potential. It's on the watch list for a lot of the major alerts sites. Prophet Alerts gives top notch alerts like OPTR. I just found them recently but have been surprisingly impressed.
This is a real once in a lifetime opportunity ..GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !
IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013 includes a potency drug which is better than Viagra . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and current Market cap of just $31 M is really a BIG BIG BARGAIN .
My Target is $8-12 within 2 Years .GLTA
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
High of $14.48... do they have an offer? Or did the shorts get greedy and bump it up? I'll take the buyout as it is more positive than the shorties.